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Abstract
Background—Mammographic density (MD) is a strong marker of breast cancer risk, but it is
unclear whether tumours arise specifically within dense tissue.
Methods—In 231 British women diagnosed with breast cancer after at least one negative screen
during a mammographic screening trial, we assessed whether tumour location was related to
localised MD 5 years prior to diagnosis. Radiologists identified tumour locations on digitized
diagnostic films and used a validated algorithm to align serial images from the same woman to
locate the corresponding point on the pre-diagnostic film. A virtual 1cm-square grid was overlaid
on pre-diagnostic films and MD calculated for each square within a woman’s breast (mean=271
squares/film). Conditional logistic regression, matching on a woman’s breast, was used to estimate
the odds of a tumour arising in a square in relation to its pre-diagnostic square-specific MD.
Results—Median (inter-quartile range) pre-diagnostic MD was 98.2% (46.8%-100%) in 1cm-
squares that subsequently contained the tumour and 41.0% (31.5%-53.9%) for the whole-breast.
The odds of a tumour arising in a 1cm-square were, respectively, 6.1 (95%CI: 1.9, 20.1), 16.6
(5.2, 53.2) and 25.5-fold (8.1, 80.3) higher for squares in the 2nd, 3rd and 4th quartiles of pre-
diagnostic MD relative to those in the lowest quartile within that breast (Ptrend<0.001). The
corresponding odds were 2.3 (1.3, 4.0), 3.9 (2.3, 6.4) and 4.6 (2.8, 7.6) if a 3cm-square grid was
used.
Conclusion—Tumours arise predominantly within the radiodense breast tissue.
Impact—Localised MD may be used as a predictor of subsequent tumour location within the
breast.
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Introduction
Mammographic density (MD), which reflects the amount of radiodense fibroglandular tissue
in the breast, is one of the strongest known markers of susceptibility to breast cancer. High
MD (i.e dense tissue occupying >75% of the breast) is associated with a 4-6 fold increased
breast cancer risk relative to women with little density (<5%) (1-2), with a third of breast
cancers in high-risk populations being attributable to MDs over 50% (2-3). Although high
MD is associated with a greater subsequent breast cancer risk, it is not known whether MD
is directly related to risk, with tumours arising within the radiodense tissue itself, or simply a
marker of susceptibility, that is both MD and breast cancer risk have common determinants
(e.g. parity) but MD is not an intermediate factor between such determinants and cancer.
Reductions in MD have been shown to be associated with reduced breast cancer risk,
although not consistently (4-6). Clarification of whether MD is directly related to risk, or
simply a correlate of its determinants, will enhance our understanding of the pathogenesis of
breast cancer and will provide information on the value of using localized MD as a predictor
of subsequent tumour location, possibly opening up new avenues for the clinical
management of high-risk women.
Two previous studies have assessed whether tumours develop within radiodense areas of the
breast, but produced conflicting findings (7-8). Using diagnostic films of 22 patients with a
solitary ductal carcinoma in situ (DCIS), Ursin et al. concluded that 21 of 22 tumours were
located within dense tissue (7). However, temporality could not be established and thus the
results might have arisen from dense tissue being more likely to undergo carcinogenic
transformation or from proliferation of the dense stromal tissue as a consequence of
developing tumour. Vachon et al. examined pre-diagnostic mammograms of 350 breast
cancer cases (invasive and DCIS) and, in contrast, found no association between the breast
quadrant with highest density either 3 or 7 years prior to diagnosis and the quadrant location
of the subsequent tumour (8). Both studies relied on a quadrant approach to examining
localized breast density. Densities can be either diffuse or focal in nature (9), thus, using too
large a region, such as a quadrant, might not yield an accurate measure of density in the
specific area where the tumour arises.
The present study aims to determine whether, in women who subsequently develop breast
cancer, localised dense areas of the breast several years prior to diagnosis were at a greater
risk of being the location of the subsequent tumour than less dense areas within that same
breast. To achieve this we used a novel approach (10) to align a woman’s pre-diagnostic and
diagnostic mammograms and measure localized MD for much smaller areas than previously
(e.g. 1cm2 squares) in mammograms taken several years prior to cancer diagnosis.
Material and Methods
Study population
The study was conducted within the Age Trial, a British trial of annual mammographic
screening (11). Women randomized to the intervention arm (~54,000) between 1991 and
1997 were offered annual breast screening from age 39-41 to age 48 years. From age 50
onwards, they were invited for screening every 3-years as part of the UK National Health
Service (NHS) Breast Screening Programme (BSP). Screening in the trial was by two-view
x-ray mammography, cranio-caudal (CC) and medio-lateral oblique (MLO) views, at the
first screen and by MLO view thereafter. Women were followed up through the BSP and the
NHS Central Register to ascertain cancer incidence. Participants in the present study were
women in the intervention arm of the trial who were diagnosed with breast cancer before
31st December 2007 after having undergone at least one negative screening round. The study
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was approved by the UK South East Research Ethics Committee. Participants provided
written informed consent.
Tumour location on diagnostic films
Diagnostic and pre-diagnostic mammograms were retrieved from screening centres and
hospitals and digitized on an Array 2905 laser digitizer (optical density 0-4.0, 12-bit
resolution, pixel length 50 μm) (Array Corporation Europe, Roden, The Netherlands). On
the digitized diagnostic MLO image displayed on a normal computer screen in a darkened
room, the tumour location was marked by one of two radiologists (CR, LW) (Figure 1A),
with a randomly selected 6% independently marked by both radiologists twice. Histology,
pathology and radiology reports, available for all but two cases, were provided. Within-
radiologist mean distance (95% confidence interval (CI)) between tumour points
independently marked were 1·04 (0·52-2·08) mm and 1·71 (1·44-2·03) mm for the two
radiologists. The median (inter-quartile range, IQR) between-radiologist difference between
tumour points was 1.73 (1·52-7·70) mm.
Identification of the point on pre-diagnostic films where the tumour originated
The MLO film five years prior to diagnosis, or nearest to this date, was selected throughout.
The point on the pre-diagnostic film (of the same breast) that corresponded to the identified
tumour location point was found using an automated affine registration method to align
serial (time-separated) mammograms from the same woman. This point on the pre-
diagnostic image was treated as the point at which the subsequent lesion develops (Figure
1B). Variations in the imaging process (e.g. positioning, degree of breast compression)
cause the breast to appear at different positions in serial mammograms (Figure 1A). We had
previously optimised three intensity-based automated registration methods - affine, fluid and
free-form deformation - specifically to provide accurate alignment of serial x-ray
mammograms. We evaluated the accuracy of these optimised registration algorithms against
five film-readers who independently identified landmarks (i.e. tumour and normal features
such as nipples and ligaments) on 52 pairs of diagnostic and corresponding pre-diagnostic
digitized images. Registration errors for each one of the three algorithms were calculated as
the distance between the registered point (i.e. the film-reader’s feature location on the
diagnostic image transformed onto the pre-diagnostic image) and the corresponding feature
location on the pre-diagnostic image identified by the film-readers, the latter taken as the
“gold standard” (10). The affine method had the highest accuracy, similar to that between
independent film-readers, with 80% of affine registration errors being <1cm and 100% being
<2cm (10).
As the affine registration is an intensity-based method (i.e. an intensity defined similarity
measure of corresponding pixels is maximised) we excluded a circle around the tumour
centre on the diagnostic image to avoid the tumour being aligned to pre-diagnostic density
tissue thus creating a biased positive association. The circle’s diameter was the tumour size
from the pathological report, if available (n=129, 56%), or diameters of 18mm (if only an
invasive component was present) or 20mm (otherwise) (Table 1).
Whole-breast and square-specific density readings
MD readings were performed on the pre-diagnostic MLO films by a single reader (VM),
blinded to subsequent tumour location, using the interactive threshold Cumulus method (12).
This method dichotomizes pixels on a digitized mammogram according to their intensities
into dense and non-dense using the threshold defined by the user, automatically estimating
dense and total breast areas (in cm2) and their ratio (as percent MD). Thirty-five (9%) films
were read twice, giving a high repeatability (intra-class correlation coefficient for percent
MD 0·97; 95% CI 0·95-0·98). An investigation of these breast cancer cases and of controls
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randomly selected among breast cancer-free Age Trial participants - closely matched to each
case on screening centre, date of birth (±1 year) and date of mammogram (±1 year) - showed
a strong association between pre-diagnostic whole-breast percent MD and subsequent breast
cancer risk (MD>75% was associated with a 6.6-fold (95% CI 2.1, 20.5) increase in risk
relative to MD<25%).
A semi-automated method was specifically developed to overlay a square grid on the pre-
diagnostic image such that the square containing the tumour location was centered on that
point (Figure 1B). The co-ordinate points of the grid squares were then fed into the “mask”
Access database sheet of Cumulus to generate a series of images from the same breast that
sequentially showed each square of the breast, one at a time.Thereafter, using the same
intensity threshold selected to determine whole-breast percent MD, we calculated the
percent MD in each grid square, i.e. square-specific MD, using the Cumulus software. For
the same grid size, percent MD in a given square is directly proportional to absolute dense
area. A grid size with squares of 4cm length was initially used as affine registration errors
are less than 2cm either side of the location identified by the film-readers (“gold standard”)
(10). As this grid size minimised misclassification in identifying the tumour-square but
reduced the accuracy of the localised MD measurements, we also estimated square-specific
MD for grid sizes of 3, 2 and 1cm. Finally, we repeated MD measurements (whole-breast
and square-specific) using a higher intensity threshold to capture a more-specific small area
of extremely dense tissue. This was done to capture the highest concentration of dense
tissue, mimicking what would be the largest thicknesses of dense tissue in a volumetric
method. Whole-breast mean percent density (standard deviation, SD) 5-years prior to cancer
diagnosis was 42.4% (16.3%) with the usual intensity threshold, but only 7.7% (4.6%) with
the ‘extremely high dense’ one.
Statistical Methods
The study design lends itself to a matched case-control analysis, in which the matching set is
a woman’s breast, the square in which the tumour is subsequently located is the “tumour-
square”, and all other squares are “tumour-free squares”. Along the edge of the breast some
squares were smaller than the defined grid size because any non-breast features located
within them (e.g. pectoral muscle) were masked and excluded. Thus, only tumour-free
squares whose areas were within 10% of the tumour-square area were included. If no
tumour-free squares were within this size range, the case-control set was excluded (n=3 and
n=8 for the 1 and 3 cm grids, respectively).
Conditional logistic regression was used to estimate the odds of a square later becoming the
tumour-square versus remaining tumour-free in relation to the square-specific MD and
within-breast quartiles of square-specific MD. The analysis was repeated using pre-defined
categories of square-specific MD (i.e. <10%, 10-29%, 30-79% and ≥80%). As analyses were
matched on the woman’s breast, woman-level variables (e.g. age) did not vary within a set/
breast so could not, as a main effect, influence the outcome within a woman. Effect
modification by these variables was, however, examined.
Results
Radiologists viewed diagnostic films for 284 breast cancer cases and were able to identify a
tumour on 236 (83%). This analysis comprised 231 cases (five were excluded because of
different sized pre-diagnostic/diagnostic films) diagnosed during 1994-2007. Characteristics
of the participants’ pre-diagnostic films, and of their tumours, are shown in Table 1. By
design the pre-diagnostic images were taken, on average, five years (median=4·9,
IQR=3·4-5·1) prior to diagnosis. A similar number of tumours occurred in the left and right
breasts (Table 1), most located in the upper region.
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Pre-diagnostic mean percent MD was 42·4% (SD=16·3%) for the whole-breast. In contrast,
pre-diagnostic mean percent MD for the tumour-square was 73·8% (SD=36·2%, highly
skewed (median=98·2%, IQR=46·8%-100%)) using a 1cm grid and 68.5% (SD=31.4,
(median=78.1%, IQR=47.3%-96.8%)) for a 3cm grid. The higher average percent MD in
tumour-squares compared to the whole-breast is illustrated in Figure 2A for a 1cm grid,
where most points lie above the equality line; many tumour-squares were entirely dense,
with 64% having MD>80%, such that the distribution of MD in tumour-squares was entirely
shifted upwards with little overlap with the distribution of whole-breast MD (Figure 2B).
The distribution of percentiles of within-woman square-specific MD for tumour-squares was
right skewed. In 25% of women, density of the tumour-square for the smallest grid size
(1cm) was, pre-diagnostically, within the top 10% of most dense squares, while in 75% of
women, the tumour-square was within the top 35% of most dense squares. The
corresponding figures for the other grid sizes were of a similar magnitude (e.g. respectively,
within the top 9% and top 32% for a 3cm grid).
There was a dose-response relationship between the within-woman square-specific MD
quartile and the odds of that square being the location of the subsequent tumour (Figure 3,
Table 2). For the smallest grid size (1 cm), 57% of squares that were to become tumour-
squares had MD in the top quartile of the within-breast MD distribution; only 15% had MD
in the bottom half (Table 2). Correspondingly, the odds (95% CI) of a tumour being located
within a given square were, respectively, 6·1 (1·9-20·1), 16·6 (5·2-53·2) and 25·5 (8·1-80·3)
times higher in squares in the 2nd, 3rd and 4th quartiles of within-breast MD distributions
relative to those in the lowest quartile (Table 2). The magnitude of the association was
strongest for the 1cm grid, albeit with wider CIs due to very few tumours arising in the
reference (lowest density) category, and was attenuated for larger grid sizes (Figure 3, Table
2). Taking the more stable highest quartile as the reference category yielded ORs of breast
cancer in the 3rd, 2nd and 1st quartiles of 0·65 (0·47-0·90), 0·24 (0·16-0·36) and 0·04
(0·01-0·12), respectively, for a 1cm grid. Alternatively, for the pre-defined categories of
square-specific MD, ORs were 2·35 (1·18-4·65), 5·00 (3·01-8·31) and 9·28 (5·88-14·65) for
percent MD of 10-29%, 30-79% and ≥80% relative to <10%.
The association between within-woman square-specific MD quartiles and subsequent
tumour location was not modified by pre-diagnostic whole-breast MD (0%−, 20%−, 40%−
and 60%+), time between pre-diagnostic film and cancer diagnosis (<5 and ≥5 years), or the
nature (exclusively non-invasive vs. invasive/non-invasive), grade (1/2 vs. 3) and size
(<20mm vs. ≥20mm) of the tumour (P for interaction: ≥0·12 in all for a 3cm grid; P≥0·28 in
all for a 1cm grid).
Using the “extremely high dense” threshold, ORs (95% CI) were 1, 1·2 (0·5-3·0), 1·7
(1·0-2·8) and 4·7 (3·5-6·3) for percent of extremely high density in the square being <2·5%
(reference category), 2·5-4·9%, 5·0-19·9% and ≥20·0%, respectively. 36% of tumour-
squares, but only 1·7% whole-breasts, had squares with ≥20% extremely high density.
Discussion
This study demonstrates that breast tumours arise predominantly within pre-diagnostic
radiodense tissue. The probability of an area subsequently developing into a tumour
increased as the amount of radiodense tissue in that area increased, strongly suggesting that
it is specifically concentrations of radiodense fibroglandular tissue that are at risk of
undergoing malignant transformation.
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Strengths and limitations
Previous studies (7-8) assessed whether tumours originated within the quadrant with the
highest pre-diagnostic MD. Applying this approach to our data yielded a rather weak
association (P=0·07) because 75% of our tumour-squares (regardless of grid length) had a
higher density than the highest density quadrant. The use of a validated registration
technique (10) to accurately align serial digitised mammograms is a major strength of our
study because it allowed the measurement of localised MD at a much smaller level. The
accuracy of the affine registration is somewhat lower for images with little density (10), but
it is unlikely that this affected substantially our findings because practically all pre-
diagnostic images had some density (5th percentile of pre-diagnostic whole-breast MD:
16·8%) and the magnitude of the association between square-specific MD and tumour
location did not vary according to pre-diagnostic whole-breast MD level.
Radiologists were unable to identify the tumour on the diagnostic films for 17% of cases,
mainly because their breasts were dense. This, coupled with the fact that these cases had
higher pre-diagnostic whole-breast MD than those included in the study (mean difference
7·8%, 95% CI 2·6%-13·0%), provides further indirect support to the hypothesis that tumours
arise predominantly within pre-diagnostic dense tissue. As density, and its spatial
distribution within the breast, change with age, it would be informative to assess images
taken further back in time. The participants were mainly pre-menopausal at diagnosis.
Replication of the findings in post-menopausal women of screening ages is particularly
relevant as overall MD is lower, hence, small amounts of radiodense tissue would be
identified as at-risk.
The density measurements had a high reliability, and were performed blindly to subsequent
tumour location, but the interpretation of the findings is constrained by the two-dimensional
nature of the interactive threshold method. Three-dimensional imaging methods (e.g.
magnetic resonance imaging (MRI), breast tomosynthesis) (13-14) will provide a better
assessment of the value of localised density as a predictor of subsequent tumour location,
but they will need to be modified to incorporate quantification of whole-breast and localised
amounts of fibroglandular tissue.
Relevance of the findings
The significance of the findings is twofold. First, they suggest that MD is directly involved
in the pathogenesis of breast cancer. Second, the findings provide new avenues for the
clinical management of women with high MD.
The biological basis for the MD-breast cancer association is not well characterised. Our
findings suggest that high MD is likely to be causally related to breast cancer rather than a
simple correlate of its determinants. Breast cancer arises from epithelial cells lining the
ducts or lobules of the breast. The higher the number of these cells the higher the amount of
radiodense tissue and the likelihood that they may undergo a malignant transformation,
consistent with the observation that high MD is associated with increased risk of both
invasive cancer and proliferative lesions thought to be precursors of breast cancer (e.g.
ductal carcinoma in situ, hyperplasia with or without atypia, and columnar cell lesions)
(15-16). Thus, MD may reflect higher rates of epithelial proliferation, which are likely to
increase the risk of somatic mutations, epigenetic alterations and carcinogenesis, and/or
slower rates of involution (17-19). 15% of tumours arose within areas of the breast that were
in the lower half of that breast’s square-density distribution. This is consistent with the
observation that breast cancer risk is lower, but not non-existent, in women with entirely
fatty breast (1). These tumours may have arisen within the dense tissue of tumour-squares
that were not entirely fatty or through MD-unrelated pathways.
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Current breast cancer risk assessment models do not incorporate MD (20), although the
addition of this variable may increase slightly their discriminatory power (21-22), MD is
more strongly associated with breast cancer risk than any of the variables included in the
Gail’s model (23), the most widely used risk-prediction model, and unlike most of these
variables MD may be modified by hormone interventions (e.g. tamoxifen (24)). If MD is
causally related to breast cancer, as strongly implied by our findings, factors that reduce
within-woman MD are likely to lower risk and improve detection of early lesions by
increasing the sensitivity of mammography.
Whole-breast MD, along with other independent risk factors, allows identification of women
at high breast cancer risk. Once a woman is considered as high-risk, our findings imply that
examination of localised MD may provide information on the likely location of a subsequent
tumour within a breast. The ability to identify, within a specific breast, the tissue that is at
increased risk may open up the possibility of more localized approaches for the management
of high-risk women - e.g. localized dense tissue excision, localized preventive
chemotherapy, targeted radiotherapy could be explored in future studies, as in the present
case-only study specificity could not be assessed. Cancer detection (including computer-
assisted systems) could focus more on localised patterns of density and their between-screen
changes. Under current UK guidelines (25), a woman with a predicted risk >8% from age 40
to 49 years or a lifetime risk >30% should be offered tertiary care, including additional MRI
screening and consideration of risk-reduction surgery (i.e. prophylactic mastectomy and/or
oophorectomy). Prophylactic mastectomy reduces breast cancer risk by 90-100% (26-27),
but is the least acceptable option (27). Intensive screening yields frequent false positives,
overdiagnosis and overtreatment (28). No randomised trials have compared the benefits
from these various strategies, and it is unlikely that such trials will ever be possible as
patients, and their clinicians, are unlikely to accept random assignment between prophylactic
surgery and intensive screening. Our findings among breast cancer cases need to be
replicated in follow-up studies of high-risk women undergoing repeat-screen
mammography, but if confirmed, they could lead to the development and evaluation of new
localized approaches as alternatives to prophylactic mastectomy or intensive screening.
Conclusions
Whole-breast density is a well established risk factor for breast cancer. This study goes a
step further by clearly demonstrating that tumours arise predominantly within localised
(1cm2 squares) areas that were radiodense several years prior to diagnosis.
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Figure 1.
Image registration and tumour location: (A) Diagnostic and pre-diagnostic images overlaid
on each other, with tumour point identified on diagnostic image; (B) Pre-diagnostic image
with registered tumour point located on it and overlaid square grid.
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Figure 2.
Whole-breast versus tumour square-specific mammographic density (MD) in pre-diagnostic
images: (A) Tumour square-specific percent density plotted against the corresponding
whole-breast density for the same breast (the straight line represents the line of equality);
(B) Relative distribution of whole-breast and tumour-square density values among all study
participants.
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Figure 3.
Odds of a tumour developing in a given square in relation to its pre-diagnostic square-
specific mammographic density (MD), by grid length.
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Table 1
Pre-diagnostic mammographic measures and tumour characteristics among women with breast cancer (n=231)
Pre-diagnostic mammographic measures Mean (SD)
Age at screen (years) 42.5 (2.3)
Whole breast Breast Area (cm2) 140.4 (51.7)
Dense Area (cm2) 56.4 (25.1)
Percent MD (%) 42.4 (16.3)
Square-specific
(1 cm)
No. of squares per film 271 (81)
Tumour Characteristics N (%)
Age at diagnosis (years, mean (SD)) 46.8 (3.1)
Laterality Left 116 (50.2)
Grade a 1 39 (22.0)
2 80 (45.2)
3 58 (32.8)
Whole Tumour diameter (mm, n=129) 18 (13, 27) b
Non-invasive component present c 172 (76.2)
 of which: Ductal carcinoma in-situ 159 (92.4)
Lobular carcinoma in-situ 18 (10.5)
Other in-situ 1 (0.6)
Maximum diameter (mm, n=42) 19 (12, 25) b
Invasive component present 182 (78.8)
 of which: Ductal 149 (81.9)
Lobular 28 (15.4)
Tubular/cribiform 14 (7.7)
Medullary, mucoid, other 7 (3.8)
Maximum diameter (mm, n=164) 18 (13, 27) b
MD = mammographic density
a54 missing, percentage out of non-missing
b
Median (inter-quartile range)
cNo. of exclusively non-invasive lesions=43; no. of cancers with both invasive and non-invasive components=182; no. with missing
information=6. Percentage out of non-missing
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Table 2
Odds of a square becoming the location of a subsequent breast tumour in relation to its percent
mammographic density 5 years prior to diagnosis
Grid length
(cm)
Within-breast quartiles
of square-specific
percent MD
No. of squares in
which tumour arises a
OR (95% CI) b
4 1 (lowest) 26 1
2 48 1.5 (0.9, 2.5)
3 66 2.5 (1.6, 4.1)
4 (highest) 74 2.6 (1.6, 4.2)
P for linear trend < 0.001
3 1 (lowest) 19 1
2 44 2.3 (1.3, 4.0)
3 69 3.9 (2.3, 6.4)
4 (highest) 91 4.6 (2.8, 7.6)
P for linear trend < 0.001
2 1 (lowest) 15 1
2 32 2.1 (1.1, 3.8)
3 71 4.9 (2.8, 8.6)
4 (highest) 111 6.4 (3.7, 11.1)
P for linear trend < 0.001
1 1 (lowest) 3 1
2 32 6.1 (1.9, 20.1)
3 63 16.6 (5.2, 53.2)
4 (highest) 130 25.5 (8.1, 80.3)
P for linear trend < 0.001
MD=mammographic density
a
The total number is less than 231 because tumour-squares for which no control squares of similar size (i.e. within 10%) could be identified were
excluded (see Methods section).
bOdds ratio (OR) and 95% confidence interval (CI) estimated using a conditional logistic regression model where the matching set is a woman’s
pre-diagnostic breast consisting of a square where the tumour will subsequently originate (tumour-square) and several tumour-free squares
(control-squares) (see Methods section).
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